Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Marck Biosciences Ltd.
WARNING LETTER
•Marck Biosciences Ltd.•November 1, 2013

Marck Biosciences Ltd. – FDA Warning Letter, Nov 1, 2013

Record Details

An FDA inspection of Marck Biosciences Ltd.'s pharmaceutical manufacturing facility in Kheda, India, from October 29 to November 1, 2013, revealed significant violations of current Good Manufacturing Practice (CGMP) regulations (21 CFR Parts 210 and 211), rendering their drug products adulterated. The firm's subsequent response was deemed insufficient. Key violations included failure to maintain accurate batch production and control records, evidenced by discrepancies between official and unofficial records, use of scratch paper, and falsified activities. The firm also failed to maintain adequate equipment maintenance records, ensure proper personnel training (including untrained contract employees and falsified training documents), follow storage and warehousing procedures, maintain clean and sanitary facilities (noting mold and pest infestations), and exercise strict control over labeling. The FDA expressed serious concerns about data integrity, requiring a comprehensive corrective action plan, including the engagement of a third-party auditor to investigate data manipulation, audit distribution practices, and review all data submitted to the FDA. Failure to correct these violations may result in the withholding of new application approvals and refusal of admission for products into the U.S. The firm was required to respond within fifteen working days with specific corrective and preventive actions.

Company
Marck Biosciences Ltd.
Inspection date
November 1, 2013
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Thomas J. Cosgrove
View Company Profile

ID · eaa654ed-0464-4f5d-ae53-fee6d26e70e5

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 211FD&C Act 501(a)(2)(B)21 CFR 211.188(b)21 CFR 211.18221 CFR 211.25(a)21 CFR 211.14221 CFR 211.56(a)21 CFR 211.125(a)

Full citation text and observation details available on the Dashboard.

Other documents for Marck Biosciences Ltd.
  • WARNING_LETTER - 2014-08-26August 26, 2014

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Marck Biosciences Ltd.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.